Rationale and budget impact of bimonthly use of Cetuximab in patients with recurrent and/or metastatic head and neck cancer.
Aged
Carcinoma, Squamous Cell
/ drug therapy
Cetuximab
/ administration & dosage
Cost Savings
Drug Administration Schedule
Drug Costs
Female
Head and Neck Neoplasms
/ drug therapy
Humans
Italy
Male
Middle Aged
Neoplasm Invasiveness
/ pathology
Neoplasm Recurrence, Local
/ drug therapy
Neoplasm Staging
budget
cetuximab
economic benefits
every-other week
head and neck cancer
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
12
01
2018
revised:
11
04
2018
accepted:
24
07
2018
pubmed:
27
1
2019
medline:
10
10
2020
entrez:
26
1
2019
Statut:
ppublish
Résumé
In recurrent and/or metastatic head and neck squamous cell cancer, Cetuximab is administered once a week, followed by weekly doses. We present the clinical rationale of a different schedule of maintenance Cetuximab and we estimate the potential economic benefits on the health care budget from a societal perspective in Italy. A budget impact (BI) excel-based model was developed comparing a base case scenario of 100% weekly administration with a dose of 250 mg/m In the EOW, 50% scenario it was calculated a cost reduction of €347 000 of which 70% attributable to indirect costs, increasing to €694 000 after 4 months. In our analysis, we showed that this simplified schedule could also reduce the costs of treatments both for the health system (direct costs) and for the society (indirect costs).
Sections du résumé
BACKGROUND
In recurrent and/or metastatic head and neck squamous cell cancer, Cetuximab is administered once a week, followed by weekly doses. We present the clinical rationale of a different schedule of maintenance Cetuximab and we estimate the potential economic benefits on the health care budget from a societal perspective in Italy.
METHODS
A budget impact (BI) excel-based model was developed comparing a base case scenario of 100% weekly administration with a dose of 250 mg/m
RESULTS
In the EOW, 50% scenario it was calculated a cost reduction of €347 000 of which 70% attributable to indirect costs, increasing to €694 000 after 4 months.
CONCLUSIONS
In our analysis, we showed that this simplified schedule could also reduce the costs of treatments both for the health system (direct costs) and for the society (indirect costs).
Substances chimiques
Cetuximab
PQX0D8J21J
Types de publication
Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
908-914Informations de copyright
© 2019 Wiley Periodicals, Inc.